PLoS ONE (Jan 2016)

Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy.

  • Raghav Sundar,
  • Anand D Jeyasekharan,
  • Brendan Pang,
  • Richie Chuan Teck Soong,
  • Nesaretnam Barr Kumarakulasinghe,
  • Samuel Guan Wei Ow,
  • Jingshan Ho,
  • Joline Si Jing Lim,
  • David Shao Peng Tan,
  • Einar P V Wilder-Smith,
  • Aishwarya Bandla,
  • Stacey Sze Hui Tan,
  • Bernadette Reyna Asuncion,
  • Zul Fazreen,
  • Michal Marek Hoppe,
  • Thomas Choudary Putti,
  • Lay Mui Poh,
  • Boon Cher Goh,
  • Soo-Chin Lee

DOI
https://doi.org/10.1371/journal.pone.0164319
Journal volume & issue
Vol. 11, no. 10
p. e0164319

Abstract

Read online

Sensory peripheral neuropathy caused by paclitaxel is a common and dose limiting toxicity, for which there are currently no validated predictive biomarkers. We investigated the relationship between the Charcot-Marie-Tooth protein NDRG1 and paclitaxel-induced neuropathy.Archived mammary tissue specimen blocks of breast cancer patients who received weekly paclitaxel in a single centre were retrieved and NDRG1 immunohistochemistry was performed on normal nerve tissue found within the sample. The mean nerve NDRG1 score was defined by an algorithm based on intensity of staining and percentage of stained nerve bundles. NDRG1 scores were correlated with paclitaxel induced neuropathy.111 patients were studied. 17 of 111 (15%) developed severe paclitaxel-induced neuropathy. The mean nerve NDRG1 expression score was 5.4 in patients with severe neuropathy versus 7.7 in those without severe neuropathy (p = 0.0019). A Receiver operating characteristic (ROC) curve analysis of the mean nerve NDRG1 score revealed an area under the curve of 0.74 (p = 0.0013) for the identification of severe neuropathy, with a score of 7 being most discriminative. 13/54 (24%) subjects with an NDRG1 score 7 (p = 0.017).Low NDRG1 expression in nerve tissue present within samples of surgical resection may identify subjects at risk for severe paclitaxel-induced neuropathy. Since nerve biopsies are not routinely feasible for patients undergoing chemotherapy for early breast cancer, this promising biomarker strategy is compatible with current clinical workflow.